Puma Biotechnology
PBYI
69 hedge funds and large institutions have $67.6M invested in Puma Biotechnology in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 20 increasing their positions, 23 reducing their positions, and 5 closing their positions.
404% more call options, than puts
Call options by funds: $1.01M | Put options by funds: $201K
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
1% more funds holding
Funds holding: 68 → 69 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.79% less ownership
Funds ownership: 56.9% → 54.1% (-2.8%)
13% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 23
28% less capital invested
Capital invested by funds: $93.8M → $67.6M (-$26.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$944K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$562K |
| 3 |
Citigroup
New York
|
+$340K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$168K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$99.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$2.64M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$525K |
| 3 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
-$448K |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
-$367K |
| 5 |
Two Sigma Advisers
New York
|
-$289K |
PBYI Hedge Fund Activity: Q3 2023 in Review
69 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2023, worth a combined $67.6M — down 28% from $93.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PBYI positions and 5 closed out — a net gain of 1 holder — while 20 added to existing stakes and 23 trimmed.
The largest buyer was Millennium Management, adding an estimated $944K. The largest seller was Hillsdale Investment Management, cutting an estimated $2.64M.
- 69 institutional investors held Puma Biotechnology (PBYI) as of Q3 2023, up from 68 in Q2 2023.
- Funds reported $67.6M of Puma Biotechnology stock for Q3 2023, down 28% quarter-over-quarter.
- 6 funds opened new Puma Biotechnology positions in Q3 2023 and 5 closed out, a net change of +1 holder.
- The largest Puma Biotechnology buyer in Q3 2023 was Millennium Management, an estimated $944K added.
- The largest Puma Biotechnology seller in Q3 2023 was Hillsdale Investment Management, an estimated $2.64M sold.
Based on aggregated 13F filings for Q3 2023.